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“We would like to take this 
opportunity to thank all those 
who submitted studies, and to 
congratulate the 11 winners 
who demonstrated excellent 
good clinical practice and the 
development of AF services to 
improve patient outcomes 
and quality of life.”
AF is the most common, sustained
heart rhythm disturbance (arrhythmia).
About 2% of the general population
have AF, and at least one in four adults
over 40 years old will develop AF in
their lifetime. It can cause distressing
symptoms, or it may remain silent, with
the patient being completely unaware
of the potentially dangerous arrhythmia
that has developed. This is one of the
main reasons that so many people have
undiagnosed AF – in excess of 30% of
people with AF are unaware.
Irrespective of symptoms, AF is
associated with severe complications,
unless it is managed and treated
eff ectively. AF-related stroke, sudden 
cardiovascular death, heart failure, 
dementia, lesser degrees of cognitive 
dysfunction, and frequent hospital 
admissions are much more common 
(stroke fi ve fold increase, other outcomes 
two fold increase) in patients with poorly
managed or untreated AF. Correct 
and expert therapy to anticoagulate 
(preventing blood clotting which 
causes an AF-related stroke and other 
complications) and to restore the normal 
(sinus) rhythm substantially reduce these 
complications. It is therefore vital that all 
patients with AF are identifi ed as early as 
possible so that anticoagulation therapy 
can begin as soon as possible.
The AF Association was established
specifi cally to help patients and their
families or carers to understand this
arrhythmia, and to obtain the best
expert advice. There are many eff ective
therapies and treatments available,
but some of the older approaches
to this arrhythmia are now known
to be ineff ective, such as aspirin as
an anticoagulant for AF, which places
patients at greater potential risk of an
AF-related stroke.
There is still a critical need to increase
the identifi cation of people with
undiagnosed AF, improve their
diagnosis, and ensure that eff ective 
and appropriate antiarrhythmic and 
anticoagulation therapy is provided
to all patients with AF. Individual 
HCPs are encouraged by international 
guidelines to take every convenient 
opportunity to test for atrial fi brillation.
The pace of change has been rapid in this 
fi eld of medicine, and the AF Association
has set up an award for Healthcare
Pioneers working in AF, to identify
innovative and positive advances in
the way diagnosis, anticoagulation
therapy, antiarrhythmic and rate control 
treatments for AF has been established in 
leading centres. These ideas are collated 
into the Healthcare Pioneers Report 
on an annual basis. This year we had 
over 25 submissions from the UK and 
abroad. Most of the submissions related 
to screening for AF, audit of medical 
practice, particularly anticoagulation, and 
managing AF in special circumstances.  
An international panel of judges 
scored the submissions according to a 
scoresheet which included originality, 
completion, patient involvement 
and implications for health care. This 
information is then disseminated as a 
model of best practice that other centres 
can adapt to improve their own practice 
in the management of patients with AF.
The AF Association – Healthcare Pioneers 
Report 2021 includes 11 case studies 
describing best practice to establish or 
grow existing services and to deliver our 
core campaign: ‘DETECT AF; PROTECT 
against AF-related stroke; CORRECT 
the irregular heart rhythm; and thereby 
PERFECT the patient care pathway – 
restoring a patient back to a person and 
improving their quality of life. We would 
like to take this opportunity to thank 
all those who submitted case studies, 
and to congratulate the 11 winners who 
demonstrate excellent good clinical 
practice and the development of AF
services to improve patient outcomes
and quality of life. Applications for the AF 
Association Healthcare Pioneers Report 
2022 will open in March 2021 – we 
encourage everyone who is aware of, or 
actively engaged in the management of 
patients with AF, to share their examples 
of best practice. The winners will be 
announced during the AF Association 
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SMART TECHNOLOGY FACILITATED EARLY DIAGNOSIS AND INTEGRATED CARE OF 
ATRIAL FIBRILLATION: THE MAFA PROGRAMME  
A/ PROFESSOR. YUTAO GUO, PROFESSOR 
YUNDAI CHEN, PROFESSOR GREGORY Y H LIP 
CHINESE PLA GENERAL HOSPITAL, BEIJING, CHINA, UNIVERSITY 
OF LIVERPOOL AND LIVERPOOL HEART & CHEST HOSPITAL, 
LIVERPOOL, UK AND AALBORG UNIVERSITY, DENMARK
Introduction: The early diagnosis and detection of 
atrial fi brillation (AF) is problematic as patients are often 
asymptomatic, and the fi rst presentation may be with an 
AF-related complication. Smart technology may help bridge 
the patient care pathway, from primary care to secondary 
care management. 
We herein present our work with targeting screening which 
was then managed with the Atrial Fibrillation Better Care 
(ABC) pathway, supported by mobile AF Application (mAF 
App): ‘A’ Anticoagulation to Avoid stroke – Anticoagulation 
with non-vitamin K antagonist oral anticoagulant (NOAC) 
or well-managed warfarin; ‘B’ Better symptom management 
with patient-centred symptom-directed shared decisions 
for rate or rhythm control; and ‘C’ Cardiovascular risk and 
comorbidity management. 
The screening programme was published as the Huawei 
Heart Study (pre-mAFA study)(JACC,2019) and the ABC 
pathway was tested as a cluster randomized trial in the 
mAFA-II trial (JACC,2020).
The Huawei Heart Study (pre-mAFA study): The PPG 
algorithm and smart devices used for the Huawei Heart 
Study was tested in 187,000 individuals who used Huawei 
smart devices to monitor their pulse rhythm between 
October 26, 2018 and May 20, 2019: 424 (0.23%) subjects 
had “suspected” AF in the general population, with the 
highest proportion of AF episodes among the elderly. 
Of the ‘suspected AF’, 87% were confi rmed as having AF. 
After entering the AF patient care pathway, 80% of patients 
at high-risk of stroke were anticoagulated.
The mAFA II trial: In the mAFA intervention group, 
the doctors used the mAFA platform which provided 
clinical decision support tools (CHA2DS2-VASc, HAS-
BLED, SAMeTT2R2 scores) that help facilitate treatment 
recommendations, educational materials and patient 
involvement strategies with self-care protocols and 
structured follow-up. 
Rates of the composite outcome of ‘ischaemic stroke/
systemic thromboembolism, death, and rehospitalization’ 
were lower with the mAFA 
intervention compared to usual 
care (1.9% vs. 6.0%, hazard 
ratio, hazard ratio, HR 0.39, 95% 
confi dential interval, CI: 0.22-
0.67, P < 0.001). In an ancillary 
analysis to the mAFA-II trial, 
dynamic monitoring of bleeding 
risks and regular re-assessments 
using the HAS-BLED score 
was associated with less major 
bleeding events, mitigation of 
modifi able bleeding risk factors 
and increased OAC uptake over 
time; in contrast, the ‘usual 
care’ arm was associated with 
higher bleeding rates and OAC 
use decreased by 25%, when 
baseline was compared to 12 
months.
Conclusions: The mAFA 
programme links AF screening 
with eligible patients who were 
subsequently entered into 
a structured care pathway with 
mHealth technologies. 
This highlights the potential 
application of mHealth 
management for AF, bridging 





AF IMPROVEMENT IN DERBYSHIRE - A COLLABORATIVE APPROACH
ADAM NOWAK, JOANNE GOODISON, DR 
TARUN NARULA, RACHEL MADIN
STRATEGIC CLINICAL CONDITIONS & PATHWAYS TEAM, NHS 
DERBY & DERBYSHIRE, UK
Derby & Derbyshire CCG have been working closely 
in partnership with colleagues from East Midlands 
Academic Health Science Network over the past few years 
on the Atrial Fibrillation agenda. The Strategic Clinical 
Conditions and Pathways team at the CCG, working 
with system partners via our CVD Delivery Board have 
achieved signifi cant improvements in AF diagnosis and 
management between March 2015 and March 2019. 
Our CVD Delivery Board meets monthly and draws in 
the key stakeholders from primary care, voluntary sector, 
secondary care and is commissioning to drive forward 
health improvement initiatives and effi  ciencies.
Detect: Based upon PHE data there was a gap in the 
primary care AF register of 8,683 patients in March 2015. 
Only 68.9% of the estimated number of patients with AF 
had been detected. 
An additional 4,683 patients have been diagnosed with AF 
between March 2015 and March 2019, with a drop in gap 
percentage from 31.1% to 14.3%
NHS Long Term Plan target for AF detection is 85% by 
2029. Derby & Derbyshire STP, as of March 2019 is at 
85.7%. We are ten years early.
Protect: March 2015 72.1% of AF patients were receiving 
anticoagulation treatment, in March 2019 87.7% are now 
on the correct therapy. The NHS Long Term Plan target is 
90% by 2029. Derby & Derbyshire STP is well on track.
Impact: It is estimated that these improvements will have 
led to a reduction in 271 strokes and 90 deaths, with 
avoided total NHS and social care costs of £5,270,000. 
How?
With support from EMAHSN Derby & Derbyshire STP 
has achieved these sizeable improvements through a 
structured process involving –
• AF & Hypertension awareness events – Hosted locally 
 to support primary care colleague attendance.
• High on agenda of Delivery Group with associated 
 project management and system savings based 
 effi  ciency targets attributed to the programme of work.
• Deployment of “free” single lead ECG devices that 
 connect to smart phones. Training events have 
 supported primary care staff  to understand the 
 importance and how to embed the use of these 
 devices into practice.
• Development time for Practice Nurses – enabled 
 focussed paid time in practice to embed single lead 
 ECG’s into clinical use by all clinical members of the 
 primary care team.
• Enabling single lead ECG’s to be deployed into 
 community specialist teams.
• Targeted letters with named practice outcomes to each 
 PCN Clinical Lead.
Next: Developing comprehensive Dashboard to ensure 
AF targets are monitored with further interventions as 




 expert allowing opportunities for shared 
 learning and discussion of individual cases; 
 Optimising treatment and management of 
 high risk AF patients
Phase 5 - Review of recommendations and subsequent 
 actions at two months post clinic to determine 
 outcomes
RESULTS
• 21 GP practices participated covering a 193,175 
 population (81% of LCCG). 2,274 patients’ medical 
 records were audited covering all patients on the AF 
 register which equated to an AF prevalence of 1.2%. 
• From 2,274 patients with AF, 1,789 were already 
 on anticoagulants (78.7%), with 34.6% (n=619) on 
 VKA medications and 65.4% (n=1,170) on DOACs. 
• Case notes were reviewed for 485 patients not on 
 anticoagulation, with 297 (61.2%) patients 
 deemed not eligible for anticoagulation. This left 
 188 (38.8%) patients who were eligible for, but 
 not on, anticoagulation.
• A further 89 (14.4%) patients currently taking VKA 
 medications were deemed sub-optimal with regards 
 to INR control with TTR <65%. Of the DOAC patients,  
 122 (10.4%) required dosage review.
• In total 399 patients were invited for review by 
 a Consultant Cardiologist at their local GP practice, 
 with an attendance rate of 72%. From all 
 face-to-face and telephone consultations, 
 354 patients had anticoagulants 
prescribed, 
 changed, management of INRs 
improved, DOAC dose increased 
or were in the process of being 
anticoagulated at the time of 
follow-up. 
From this we would expect:
14 AF-related strokes prevented
8 lives saved and a cost saving to 
the NHS of £336,000 per year. 
Data published in 2018 showed that 
39 patients with known AF have a 
stroke each year across LCCG and 
from our results we expect a 36% 
reduction.
   
CONCLUSION
A Consultant Cardiologist led 
programme across GP practices in 
LCCG has enabled improved 
anticoagulation to prevent 
AF-related stroke.
A CONSULTANT CARDIOLOGIST LED PROGRAMME TO REDUCE ATRIAL FIBRILLATION 
RELATED STROKE
ANTONY GRAYSON, ANNE GRAEFF, BEV 
STEVENS, and CAROL HUGHES
INSPIRA HEALTH LTD AND LUTON CLINICAL COMMISSIONING 
GROUP, UK
OBJECTIVE
Ensuring patients with AF are appropriately 
anticoagulated across NHS Luton Clinical 
Commissioning Group (LCCG) with the primary goal 
of reducing AF-related strokes. 
OUTLINE OF SERVICE
In partnership with Inspira Health, LCCG adopted the 
Primary Care Atrial Fibrillation (PCAF) Service model 
which is led by Consultant Cardiologists, with fi ve 
phases as follows:
Phase 1 - Running the AF-PRIMIS audits on the 
 clinical system 
Phase 2 - Completion of three clinical audits utilising 
 GRASP-AF; Comprehensive patient case note 
 review; A review of all DOAC patients, ensure 
 correct dose and in date bloods; Independent 
 assessment of warfarin patient safety 
Phase 3 - Systematic patient invitation for either 
 face-to-face or telephone consultations  
Phase 4 - Cardiologist-led clinics hosted within local GP 




INNOVATIVE ATRIAL FIBRILLATION (AF) DETECTION IN A RURAL COMMUNITY SETTING 
USING THE FIRE & RESCUE SERVICE IN CUMBRIA
NIKKI HOLDSWORTH, JUSTIN ROBINSON, 
CATHERINE MOODY, KATE MACKAY
THE ACADEMIC HEALTH SCIENCE NETWORK, 
NORTH EAST AND NORTH CUMBRIA, UK
Introduction: The North East and North Cumbria region 
has approximately 17,661 people with undetected AF 
(QOF 2018/19 data). The AHSN NENC were allocated 370 
pulse-checking devices by NHS England and a further 
100 devices were purchased by the AHSN. The aim was 
to detect AF in asymptomatic, high-risk patients, and 
devices were allocated to diff erent professional groups 
including those in non-healthcare settings such as the 
Fire and Rescue Service (FRS). Cumbria FRS used AliveCor 
as part of their Safe and Well visits which included pulse 
checking, alcohol reduction, smoking cessation, social 
wellbeing and falls, all focusing upon older, more frail and 
vulnerable people.
Outline of Service: Between January 2018 and March 
2019, a project lead trained Cumbria FRS Safe and 
Well Team on a face-to-face basis in small groups 
(<10 people). They were given a protocol for use and 
off ered support through an online video. To maintain 
engagement, they received a series of seven automated 
emails for three months after training which consisted 
of case studies and infographics. Device usage was 
monitored and feedback to the staff  and organisation. 
FRS actively promoted AliveCor’s use in North Cumbria 
and specifi cally in Eden Integrated Care Community (ICC) 
as well as Keswick & Solway ICC and Copeland ICC. 
Care pathway and/or treatment: The initial challenge 
was to obtain a route for referral from the FRS, so the 
person identifi ed with possible AF could receive a 12-
lead ECG to confi rm or refute an AF diagnosis. This was 
managed according to local ICC arrangements, with any 
possible AF diagnoses referred to the Lead GP at Eden ICC 
who contacted the patients’ practice, whereas the other 
ICCs had referrals through the Prevention Team Hub at 
FRS who then sent this onto the identifi ed person’s GP.
Results: AliveCor devices were used 169 times, detecting 
11 abnormal rhythms (6.5% detection rate). Cumbria is 
a large, rural area with some isolated communities and 
hard-to-reach individuals. For one woman, who was 
diagnosed with AF, had it not been for the visit of the 
crew, she reported that the outcome could have been life 
changing for herself and her family and could not stress 
enough the importance of taking the test when off ered, 
as it has potentially saved her life.  
Conclusion: Locating AliveCors in non-healthcare 
settings with those who can reach isolated communities 
and individuals, who may not engage with healthcare 





HARNESSING THE POWER OF CARDIAC REHABILITATION: AN EFFECTIVE INTERIM 
SERVICE TO SCREEN AND REFER IN AF MANAGEMENT
SONYA LOCKETT
UNIVERSITY HOSPITALS OF NORTH MIDLANDS NHS TRUST, UK
Patients diagnosed with Atrial Fibrillation (AF) previously 
attended Cardiac Rehabilitation (CR) programmes after a 
referral was made by an appropriate Arrhythmia Specialist 
and following their Outpatient review. The reality for the 
patient was a process that resulted in months before 
they were referred into and able to access the extensive 
support and information CR provides. CR Services 
accept a variety of Cardiovascular conditions and clinical 
observations routinely include heart rate and rhythm 
checks, irrespective of diagnosis. Our CR Service saw 2783 
patients in 2019-2020 and referral to appointment waiting 
times are currently 14-26 days; substantially earlier than 
many Specialist appointments. It was felt that there was 
a great opportunity to harness the power within CR by 
utilising the Service in the early screening and education 
of patients prior to, instead of post, Specialist review. CR 
could allay patient concerns, screen for additional needs, 
resulting in a targeted specialist consultation with a well-
informed patient.  
The Arrhythmia and CR Services worked in partnership 
to fl ip the previous referral pathway and initiated a 
referral to CR as soon as the patient was referred to the 
Arrhythmia Specialist Team. This simultaneous referral 
allowed CR to instigate a series of immediate support 
and screening processes to allow prompt treatment and 
commence referrals to additional organisations, required 
for comprehensive patient management.
All AF patients are now screened for Obstructive Sleep 
Apnoea (OSA) in CR through information packs, OSA 
screening questionnaires and patient consultation.  This 
has resulted in the successful identifi cation of positive 
patients, prompt referral to Sleep and Ventilation Services 
and the commencement of management strategies i.e 
CPAP, prior to an Arrhythmia Specialist review. Any new 
heart diagnosis can be anxiety-provoking for patients 
and lead to a period of fear-avoidance and inactivity. 
This can be immediately off set by the support processes 
in place and well-utilised by the CR Service, including 
Cognitive Behavioural Therapies, Education Groups, Ask 
the Expert AF Podcasts and other virtual resources.  The 
CR Service has a wide-ranging social media platform for 
home exercises, education sessions and online patient/
carer support groups; all trust-worthy material monitored 
and produced by CR clinicians.  Aspects of the gym-based 
programme may require prior review by a Specialist,
but there are certainly aspects of the CR Service better 
placed to support and screen patients in the interim, 
and the success of this project undoubtedly lies in its 




DOING SIMPLE THINGS WELL: PRACTICE ADVISORY IMPLEMENTATION REDUCES 
ATRIAL FIBRILLATION AFTER CARDIAC SURGERY
Dr MARTINA BUERGE, ROSALIE MAGBOO, Dr 
DYLAN WILLS, Prof BEN O’BRIEN
BARTS HEART CENTRE, BARTS HEALTH NHS TRUST, UK
Background: Atrial fi brillation after cardiac surgery 
(AFACS) is a very frequent complication aff ecting 30-50% 
of all patients following heart operations. It is associated 
with increased morbidity, mortality and hospital and 
intensive care unit (ICU) length of stay. We aimed to 
implement an AFACS prevention care bundle based on a 
recently published practice advisory [1], focusing on early 
postoperative (re)introduction of β-blockers.
Methods: Baseline AFACS incidence and β-blocker 
administration practices in our centre were audited for all 
patients undergoing valve surgery and/or coronary artery 
bypass graft (CABG) during a 6 week period. The AFACS 
prevention care bundle graphical tool was subsequently 
introduced to the cardiac ICU by a multidisciplinary team 
and audited following a model of improvement approach. 
Diff erences between pre- and post-implementation 
groups were compared using Chi-square and Fisher’s 
exact tests for categorical, and One-way ANOVA for 
continuous variables. 
Results and Discussion: Patient and surgery 
characteristics did not diff er between audit groups. After 
introducing the care bundle, we found a signifi cant 
increase in the number of patients who received 
postoperative β-blockers and a signifi cant decrease in 
the incidence of AFACS from 35.4% to 23.3% (p=0.009).  
Furthermore, β-blockers were administered earlier and 
β-blocker withdrawal, by failure to reintroduce pre-
operatively prescribed β-blockers, was reduced.
The increased use of early postoperative β-blockers 
indicates successful uptake of the new care bundle and 
translates into 191 fewer patients with AFACS per year in 
our hospital and thus a signifi cantly reduced morbidity. By 
introducing an easy to follow care bundle, we adopted a 
strategy that has proven to be highly successful in other 
areas of medicine and to our knowledge is new in the 
context of AFACS. Through this, we were able to engage 
all levels of staff  involved in patient care, maximising 
the eff ective implementation of the care bundle and 
embedding its continued use into the future. Our 
multidisciplinary team approach was paramount to the 
successful implementation of the scheme by placing joint 
responsibility for patient management on all members of 
the post-operative care team and helping to move away 
from purely consultant led decision making.
Conclusion: The implementation of the tool has led to 
changes in clinical practice which will help minimise risk 
of AFACS for the benefi t of our patients,  and potentially 
reduce hospital expenditures.
Reference: [1] O’Brien B et al. (2019)  SCVA/EACTA 
Practice advisory for the Management of Perioperative 
Atrial Fibrillation in Patients Undergoing Cardiac Surgery. J 




THE NIHR GLOBAL HEALTH RESEARCH GROUP ON ATRIAL FIBRILLATION 
MANAGEMENT: HELPING DEFINING AF CARE IN BRAZIL, CHINA AND SRI 
LANKA
GREGORY YH LIP, PAULO LOTUFO, YUTAO 
GUO, RAJENDRA SURENTHIRAKUMARAN, 
TRUDIE LOBBAN, LINDSEY COOKE, G NEIL 
THOMAS, ON BEHALF OF THE NIHR GLOBAL 
REACH AF INVESTIGATORS
(BRAZIL, CHINA, SRI LANKA, AND UNITED KINGDOM)
Atrial fi brillation (AF) is the most common arrhythmia 
globally and its main causes (hypertension, diabetes) are 
common in low/middle-income countries (LMICs), as is AF 
under-anticoagulation, leading to missed opportunities 
in preventing AF-related strokes and cardiovascular 
disease.  We have led changes in AF management in 
diverse healthcare systems by promoting AF detection, 
stroke risk assessment, enabling clinicians to manage AF 
in an integrated/holistic manner, implementing the ABC 
pathway [1], see Figure 1, adapted from [2]. 
This NIHR Global Health Group is working with 
disadvantaged populations in Brazil, China and Sri Lanka, 
which have diff erent risk profi les, healthcare systems 
and needs. By co-developing known eff ective methods 
to increase awareness of AF,  its complications and 
implementing evidence-based treatments, we aim to 
build long-term, sustainable collaborations to increase AF 
education/awareness through patients, families, 
healthcare providers, and develop research 
capacity. The program delivers locally-focused 
evidence-based research to develop patient 
pathways as models of best care to reduce 
healthcare inequalities, improve well-being and 
health outcomes that could be introduced in 
other developing countries.
Case examples:
Brazil: Project 1: defi ned the clinical 
epidemiology of AF in Brazil through analysis 
of 4-year follow-up data (Brazilian Longitudinal 
Study of Adult Health). Project 2: A community 
hospital stroke cohort (EMMA) investigated 
the impact of AF on long-term outcomes and 
anticoagulation use. Project 3: Data from >2000 
community hospital medical records of patients 
receiving OACs identifi ed key factors associated 
with poor anticoagulation and mitigation 
opportunities.  Project 4: Patient care pathway 
mapping studies using HCP/patient perspective 
interviews/focus groups examined management 
barriers and potentials to optimise care.
Sri Lanka: Project 1: A screening study 
(N=10,000) to identify unknown AF prevalence/
burden. Project 2: Evaluation of AF-mHealth platform to 
streamline AF patient care. Project 3: Investigated hospital 
AF management and secondary stroke prevention 
opportunities.
China: Project 1: Four focus groups with HCPs undertaken 
with iterative UK feedback. Project 2: Co-produced 
feasibility testing of mobile Health (mHealth) patient-
orientated education and AF management algorithm.
Conclusion:
LMIC-partners in this three year funded NIHR programme 
are identifying keys aspects throughout the identifi cation 
and management of AF pathway through research 
to bring about changes that will benefi t patients and 
infl uence future methods of AF care. We have worked 
with partners/patients/carers to address country-specifi c 
training needs, defi ned co-developed key research 
questions to assess needs, and implement eff ective 
‘value for money’ projects.
REFERENCES
[1] Lip GYH. Nat Rev Cardiol. 14(11):627-628;2017.





PROTECTION OF PATIENTS WITH ATRIAL FIBRILLATION (AF) IN PRIMARY CARE:  
OUTREACH EDUCATION THROUGH CLINICAL CONSULTATIONS TO DEVELOP 
ANTICOAGULANT CONSULTATION AND DECISION MAKING SKILLS
VICKI ROWSE, SHARRON GORDON, 
CHARMAINE BRANDON
WESSEX ACADEMIC HEALTH SCIENCE NETWORK, UK
The goal of this project, funded by a Pfi zer grant, was to 
optimise anticoagulation in patients with AF in primary 
care, whilst increasing knowledge and skills of GPs and/or 
Practice Pharmacists in anticoagulation discussions.  
Brief Outline of Service
In collaboration with Dorset CCG, practices were invited to 
join the project. At each practice, an introductory meeting 
was held with the project Pharmacy Technician (PT) and 
Anticoagulant Specialist Practitioner (ASP) to outline the 
project. A knowledge and confi dence questionnaire was 
given to each clinician. The PT worked with each practice 
to audit caseloads using GRASP AF and Warfarin Patient 
Safety Tools to identify patients for review, focusing on 
patients not currently, or sub-optimally treated and at risk 
of stroke. The PT and ASP reviewed each patient’s notes, 
and the ASP held a discussion on the fi ndings with a GP 
or Practice Pharmacist. Patient Centered Decision Making 
approaches were used and anticoagulation was either 
initiated or not, as agreed with each patient. Follow up 
calls to patients were made by the PT as required 
to see how they were getting on and to reinforce 
safety messages around symptoms of bleeding.
Once patient reviews had been completed and actions 
undertaken, audits were rerun to compare data, and 
a feedback meeting was held at which post project 
knowledge and confi dence questionnaires were 
distributed. Audits were repeated six months post project. 
Results and conclusions
878 patients were reviewed across eight practices.  
Approaches to undertaking patient reviews varied 
between practices. Practices where GPs reviewed their 
own patients, rather than allocate one lead, seemed to 
have better rates of change.
The audits showed an average of 26% of patients were 
coded as AF resolved. It was often diffi  cult to fi nd the 
reason for this coding and limited processes were in place 
for reviewing these high-risk patients. Anticoagulation 
rates increased in all practices (range 1.48% - 5.72%). 
Other general fi ndings were: 
• Signifi cant numbers of patients on aspirin 
 monotherapy with no clarity on the history.  Lack of 
 pathway to review patients as they age, or their overall 
 health declines. 
• Improvements in prescribing were sustained after 
 six months. Warfarin prescribing decreased.
• Clinicians knowledge increased in 16/19 areas and 
 confi dence in 11/15 areas. Links with Secondary Care 
 Anticoagulation Services also improved. 
We are exploring a model of Primary Care Network (PCN) 
Pharmacists and PTs leading regular medicines audits and 
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COMMUNITY NURSES PREVENTING AF-RELATED STROKE IN HIGH RISK CARDIAC 
PATIENTS
NIKKI HOLDSWORTH, ANDY BAKER, KATE 
MACKAY
THE ACADEMIC HEALTH SCIENCE NETWORK, 
NORTH EAST AND NORTH CUMBRIA, UK
Introduction: The North East and North Cumbria region 
has approximately 17,661 people with undetected AF 
(QOF 2018/19 data).  The AHSN NENC, were allocated 
370 hand-held pulse-checking devices, AliveCor 
Kardia, by NHS England with the aim of detecting AF 
in asymptomatic, high-risk patients.  Devices were 
allocated to diff erent healthcare professional groups 
including community nurses such as heart failure nurses, 
cardiology nurses and physiotherapists within the Cardiac 
Rehabilitation team, Community Stroke & Rehabilitation 
team and Community Nursing team. They work with 
patients who have existing cardiology conditions or 
who have suff ered a previous stroke and likely to be at 
higher risk of developing AF. The nurses were located in 
Northumbria, County Durham and Darlington, and North 
Tees and Hartlepool.
Outline of Service: Between January 2018 and March 
2019, a project lead trained the community nurses on a 
face-to-face basis in small groups (less than ten people). 
They were given a protocol along with supporting 
resources. To ensure engagement remained high, they 
received a series of seven automated emails for three 
months after training. These consisted of case studies and 
infographics. Device usage was monitored and fedback 
to the nurses and their organisations. Motivation was 
maintained with reward and recognition at team meetings 
for those with high usage.
Care pathway and/or treatment: Any patients detected 
with an irregular pulse were referred for a 12-lead ECG to 
confi rm or rule-out AF.
Results: Over 14 months, the AliveCors were used 1,086 
times, detecting 251 abnormal rhythms and potentially 
saving ten strokes. This was a detection rate of one in 
four. These teams reported the hand-held device helped 
with work effi  ciencies, detecting new AF cases more 
quickly, reducing impact on hospital services with less of 
a requirement for 12-Lead ECGs and instant transfer of 
readings to a cardiologist for real-time advice.
Patients responded positively to the immediate 
reassurance which could be provided, along with the 
reduced need for hospital 12-lead ECG appointments.
Conclusion: Locating AliveCors to community cardiology 
nurses proved to be benefi cial in detecting people 
with undiagnosed AF. They generated the highest 
detection rate of all settings used at 23%. There was 
also an unexpected, reported benefi t around improving 
service effi  ciencies with increased remote monitoring, 
demonstrating that new technology can positively impact 
work processes along with improving eff ective clinical 




SCREENING FOR ATRIAL FIBRILLATION WITHIN A SOUTH ASIAN COMMUNITY SETTING 
USING A SINGLE-LEAD ECG
DR SUKVINDER KAUR BHAMRA, DR SARAH 
CORLETT,  PROF ALISTAIR MATHIE, 
MR VILIUS SAVICKAS, DR ADRIAN 
STEWART, DR EMMA VEALE 
THE PHARMACISTS DETECTING ATRIAL FIBRILLATION RESEARCH 
TEAM, MEDWAY SCHOOL OF PHARMACY, UNIVERSITIES OF KENT 
AND GREENWICH, UK
INTRODUCTION: Timely detection and treatment of AF 
is amongst the Government’s cardiovascular priorities. 
Several initiatives have demonstrated the potential of 
AF detection using single-lead electrocardiogram (SL-
ECG) technology in primary care settings, such as general 
practitioners’ (GP) surgeries. Unfortunately, some AF 
patients, including those from ethnic minorities, may not 
routinely engage with main-stream healthcare and may 
go undetected. Compared to White British, South Asians 
have a higher prevalence of cardiovascular risk factors, 
however fewer are diagnosed with AF. This study aimed 
to ascertain the feasibility of opportunistic AF screening 
within a South Asian community delivered by supervised 
pharmacy undergraduates using SL-ECG devices. 
OUTLINE OF SERVICE: This was a collaboration between 
the Universities of Greenwich and Kent, the AF Association 
and two Sikh temples (Gurdwaras) in Gravesend and 
Sheffi  eld. Six pharmacy students of British Indian ethnicity 
were trained by a clinical pharmacist to record SL-ECG 
using AliveCor Kardia Mobile® devices. Individuals aged 
≥18 years were invited to participate at the Gurdwara in 
Gravesend during the Global AF Aware Week (November 
2019) and at the Gurdwara in Sheffi  eld during a public 
health event in March 2020. Researchers provided 
eligible participants with information about the study and 
obtained written consent. All participants underwent a 
30-second SL-ECG test with a student under supervision 
by a clinical pharmacist and were given a provisional 
diagnosis. They were also asked to complete an optional 
feedback questionnaire. Participants with ‘Possible AF’ or 
inconclusive diagnoses were referred to their GP. SL-ECG 
traces were retrospectively over-read by a cardiologist to 
determine diagnostic accuracy. The economic impact was 
also evaluated. 
RESULTS: 608 participants (average age 60.0, 96.1% 
British Indian, 53.5% female) were screened at the two 
Gurdwaras and ten (1.6%) were given ‘Possible AF’ 
diagnoses. The cardiologist approved fi ve out of ten 
‘Possible AF’ cases (0.8%) and three (0.5%) qualifi ed for 
oral anticoagulants (average CHA2DS2VASc of 3.8). 324 
participants (53.3%) completed a feedback questionnaire. 
More than 60% were unaware of AF or associated risks 
but 97.8% felt the screening was important. Respondents 
valued the accessible and informative service at their local 
Gurdwara and 98.4% were happy to engage the following 
year. AF screening was cost-eff ective at £2,437 per 
quality-adjusted life year gained.
CONCLUSIONS: Trained pharmacy undergraduates can 
successfully use SL-ECG devices to screen a large cohort 
of individuals for AF within a South Asian community 
setting over a short period of time. This helps identify 
at-risk patients and produces economic benefi ts.
ACKNOWLEDGMENTS: Dr Gurjit Kaur Barn; Alisha 
Chandla; Bhavisha Chavda; Safa Kapadi; Anil Kumar; 





OPPORTUNISTIC SCREENING FOR ATRIAL FIBRILLATION AMONG CULTURALLY AND 
LINGUISTICALLY DIVERSE COMMUNITIES IN AUSTRALIA  
PROFESSOR TISSA WIJERATNE
UNIVERSITY OF MELBOURNE, AUSTRALIA AND SRI LANKA
Aim: To determine whether community events provide 
useful opportunities to screen and therefore provide 
potential early interventions in the Sri Lankan community 
for Stroke risk factors, such as: paroxysmal Atrial 
Fibrillation (pAF) in people aged >65 years; Type two 
Diabetes Mellitus; and Migraine (fi rst such study ever to 
be conducted in Australia).
Background: Stroke is a leading cause of disability and 
mortality in Australians. pAF, Diabetes and Migraines 
are known associated risk factors but are frequently 
underdiagnosed and often suboptimally controlled. 
To address this, we can utilise previously validated 
devices, such as the single lead non-invasive electrode 
for AF, and validated questionnaires, such as the 
AUSDRISK questionnaire for Diabetes and ID-Migraine 
screening tool, for early identifi cation and thus referral 
to appropriate healthcare professionals for further 
management. This may reduce the overall disability of 
Stroke and improve quality of life signifi cantly.
Methods: Sri Lankan Australians were invited to 
participate in community health screening programs 
where baseline information such as demographics 
and CHA2DS2VASc score was collected. T2DM risk was 
determined using the AUSDRISK questionnaire, BMI 
calculation and lifestyle questionnaire. Results were then 
discussed with participants with provision of lifestyle 
advice. Random blood glucose testing was off ered to 
“high risk” participants based on AUSDRISK, and those 
testing ≥7.0mmol/L were advised to check their HbA1c 
with their General Practitioner. Re-assessment of the 
same participants will be conducted in one year with the 
same method as described. Cardiac rhythm for pAF was 
conducted with a one lead non-invasive device recording 
with two fi ngers on the electrodes for 30 seconds. If an 
“unclassifi ed” or “irregular” rhythm was detected, these 
participants were referred for a 24 hour Holter test to 
diagnose AF. The ID-migraine questionnaire screened 
participants for their risk of migraine with those scoring 
≥2 being directed to appropriate management services.
Results: 24% (11/45) had “unclassifi ed” rhythms and 63% 
(7/11) of these participants were female. 11% (5/45) of 
participants had a positive ID-Migraine score with 60% 
(3/5) of these with no previous diagnosis of Migraine. 
Preliminary results of AUDSRISK assessment indicate that 
a high proportion of participants in “high risk” category 
had relative low healthy lifestyle and dietary knowledge.
Conclusion: Our preliminary results indicate that 
community based screening programs are feasible and 
safe and addresses important Stroke risk factors such as 
pAF ,Migraine; and glycemic control. Early detection and 
management with pharmacological agents or lifestyle 
modifi cation may mitigate Stroke disability and mortality 
outcomes. We hope to continue to expand this project to 
other culturally and linguistically diverse communities in 
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AF fact fi le
Ablation for AF




Living with AF and atrial fl utter 
Mindfulness and healthy living with AF
Oral anticoagulant therapy
Preventing AF-related stroke
The heart, the pulse and the ECG
Atrial fi brillation patient information
Cardioversion of AF
Drugs 
Treatment options for AF
AF and heart failure
Bereavement - Life following the loss 
 of a loved one
Checklists
AF
Patient & primary care
Factsheets







AF and aspirin: Frequently asked questions
Atrial fi brillation (AF)
Atrial fl utter
Being a NICE patient expert
Beta blockers
Cardioversion








Miniature insertable cardiac monitor (ICM)
Pacemaker and AV-node ablation
Pill-in-the-pocket cardioversion
Rate limiting calcium channel blockers
Rate versus rhythm management
Rivaroxaban
Transcatheter closure of the left atrial appendage
Warfarin therapy
Warfarin and diet
Warfarin and other medication
What is a clinical trial?
What is a consent form?






A treatment which destroys a very small area of tissue inside 
the heart and so works to prevent rogue electrical impulses 
from interfering with the regular rhythm of the heart
Anticoagulant/Anticoagulate
Drug therapy which helps to slow the natural clotting 
speed of the blood
Antithrombotic Treatment
Treatment which reduces the risk of a blood clot forming 






A heart rhythm disorder in which the upper chambers of 




Relating to the heart
Cardiovascular
Relating to the heart and blood vessels
Cardioversion
A therapy to treat atrial fi brillation or atrial fl utter which uses 
electrical shocks to revert the heart back to a regular rhythm
CHA2DS2VASC
A method of assessing stroke risk in patients with 
atrial fi brillation: 
Congestive heart failure
Hypertension









An image of the heart using soundwave-based technology 
(ultrasound) which shows a three-dimensional image
Electrocardiogram (ECG)
A representation of the heart’s electrical activity taken 
from electrodes on the skin surface
HAS-BLED
A method of assessing bleeding risk in AF patients on 





Labile INR (measure of blood coagulation)
Elderly (over 65 years)
Drugs/alcohol
Heart Failure
The inability (failure) of the heart to pump suffi  cient 
oxygenated blood around the body to meet 
physiological requirements
Hypertension
High blood pressure – a condition that puts strain on 
the heart, leading to thickening of the heart muscle 
and increased size of the left atrium. This condition is 
associated with atrial fi brillation
Non-vitamin K oral anticoagulants (NOACs) 
Anticoagulant therapies that work in a diff erent way to 
warfarin to prevent the blood from clotting
Palpitations
A sensation in which the person is aware of a rapid, 
irregular or hard heartbeat. It can appear to skip beats or 
thump in the chest
Paroxysmal AF
Episodes of atrial fi brillation which cease without treatment
Physiologists
A healthcare professional who performs diagnostic and 
analytical procedures to assess heart rhythm disorders
QIPP
Quality, Innovation, Productivity and Prevention for a large 
scale transformation programme for the NHS aimed at 
improving quality of care and effi  ciency
Stroke
A medical condition where the brain is deprived of oxygen 
due to a blockage or a bleed
Thrombo-embolic
The blocking of a vessel by a blood clot
Transoesophageal echocardiogram (TOE)
A procedure carried out to see whether clots have formed 
in the left atrium and if so, whether a treatment option is 
safe to perform
Urinalysis
A range of tests performed on urine
Warfarin




























The Heart of AF
A one-stop educational resource for healthcare professionals
Promoting best practice in AF care by professionals, for professionals
www.heartofaf.org
www.heartrhythmspecialists.org
Join the pioneering, global, 
Heart Rhythm Specialists website
The resource provides information on local services to general healthcare 
practitioners seeking to refer a patient or in need of advisory council; 
and patients with heart rhythm disorders.  The website aims to 
bring together a comprehensive database, which can be accessed 
easily by both patients and healthcare providers. Register on 
the heart rhythm specialist website:
Founder & CEO
Trudie Lobban MBE FRCP (Edin)
Registered Charity
UK: No. 1122442
USA: Registered Non-Profi t 501 (c)(3)
Providing information, support and access to established, 
new or innovative treatments for atrial fi brillation
endorsed by
www.heartrhythmalliance.org
Affi  liate ALL-PARTY PARLIAMENTARY GROUP 
ON ATRIAL FIBRILLATION
E trudie@afa-international.org
T UK: +44 (0) 1789 867 502
USA: (843) 415 -1886
W www.afa-international.org
https://twitter.com/AtrialFibUK
https://twitter.com/AtrialFib_US
https://www.facebook.com/atrialfi brillation
https://www.facebook.com/AtrialFibrillationAssociationUS/
https://www.linkedin.com/company/atrial-fi brillation-association
https://www.youtube.com/channel/UCmWIQStpy-1mHPnkKqDnbLg
https://healthunlocked.com/afassociation
